New drug cocktail aims to boost lymphoma remission
Disease control
Not yet recruiting
This study compares two treatment combinations for people newly diagnosed with follicular lymphoma, a slow-growing blood cancer. One group gets the standard R2 regimen (rituximab and lenalidomide), while the other adds zanubrutinib (ZR2). The goal is to see if the three-drug comb…
Phase: PHASE2 • Sponsor: KeshuZhou • Aim: Disease control
Last updated May 10, 2026 11:03 UTC